Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D.
Theodore W LaetschKathleen LudwigP Mickey WilliamsSinchita Roy-ChowdhuriDavid R PattonBrent CoffeyJoel M ReidJin PiaoLauren SaguiligTodd A AlonzoStacey L BergJoyce MhlangaElizabeth FoxBrenda J WeigelDouglas S HawkinsMargaret M MooneyNaoko TakebeJames V TricoliKatherine A JanewayNita L SeibelDonald Williams ParsonsPublished in: JCO precision oncology (2024)
This nationwide study was successful at identifying patients and evaluating the efficacy of molecularly targeted therapy for rare molecular subgroups of patients in a histology-agnostic fashion. Unfortunately, there was no activity of samotolisib against tumors with PI3K/mTOR pathway alterations. Prospective trials such as the NCI-COG Pediatric MATCH are necessary to evaluate the efficacy of molecularly targeted therapies given their increasing use in clinical practice.
Keyphrases
- end stage renal disease
- ejection fraction
- phase ii study
- newly diagnosed
- chronic kidney disease
- clinical practice
- peritoneal dialysis
- prognostic factors
- young adults
- randomized controlled trial
- clinical trial
- patient reported outcomes
- open label
- squamous cell carcinoma
- drug delivery
- tyrosine kinase
- middle aged
- cancer therapy